Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

DOI
Publisher DOI
PubMed ID
25676422
Abstract
Tyrosine kinase inhibitors (TKI) have changed the natural course of chronic myeloid leukemia (CML). With the advent of second-generation TKI safety and efficacy issues have gained interest. The randomized CML - Study IV was used for a long-term evaluation of imatinib (IM). 1503 patients have received IM, 1379 IM monotherapy. After a median observation of 7.1 years, 965 patients (64%) still received IM. At 10 years, progression-free survival was 82%, overall survival 84%, 59% achieved MR(5), 72% MR(4.5), 81% MR(4), 89% major molecular remission and 92% MR(2) (molecular equivalent to complete cytogenetic remission). All response levels were reached faster with IM800 mg except MR(5). Eight-year probabilities of adverse drug reactions (ADR) were 76%, of grades 3-4 22%, of non-hematologic 73%, and of hematologic 28%. More ADR were observed with IM800 mg and IM400 mg plus interferon α (IFN). Most patients had their first ADR early with decreasing frequency later on. No new late toxicity was observed. ADR to IM are frequent, but mostly mild and manageable, also with IM 800 mg and IM 400 mg+IFN. The deep molecular response rates indicate that most patients are candidates for IM discontinuation. After 10 years, IM continues to be an excellent initial choice for most patients with CML.Leukemia advance online publication, 13 March 2015; doi:10.1038/leu.2015.36.
Date Issued
2015-03-13
Publication Type
Article
Subject(s)
Language(s)
en
Author(s)
Kalmanti, L
Saussele, S
Lauseker, M
Müller, M C
Dietz, C T
Heinrich, L
Hanfstein, B
Proetel, U
Fabarius, A
Krause, S W
Rinaldetti, S
Dengler, J
Falge, C
Burchert, A
Neubauer, A
Kanz, L
Stegelmann, F
Pfreundschuh, M
Spiekermann, K
Scheid, C
Pfirrmann, M
Hochhaus, A
Hasford, J
Hehlmann, R
Additional Credits
Journal
Leukemia
Publisher
Nature Publishing Group
ISSN
0887-6924
Access(Rights)
restricted
Show full item